What is MY01?
MY01 specializes in Continuous Perfusion Sensing Technology, a sophisticated diagnostic solution engineered to provide real-time monitoring of intracompartmental pressure. The company's flagship device is specifically designed to assist clinicians in the rapid and accurate diagnosis of compartment syndrome, a critical condition in trauma settings. By integrating seamlessly into existing hospital workflows, the technology offers actionable insights that reduce diagnostic uncertainty and improve patient safety.
Beyond its technical capabilities, MY01 has achieved significant regulatory and commercial milestones, including Medicare NTAP and TPT approvals. These designations are instrumental in facilitating reimbursement for both inpatient and outpatient procedures, thereby lowering the barrier to entry for healthcare institutions seeking to adopt advanced monitoring tools. The company's market position is defined by its commitment to reliability and user-centric design, addressing a clear clinical need in emergency medicine.
How much funding has MY01 raised?
MY01 has raised a total of $12.5M across 1 funding round:
Series A
$12.5M
Series A (2023): $12.5M with participation from Fondaction, Investissement Quebec, and Desjardins Capital
Key Investors in MY01
Fondaction
A Quebec-based investment firm focused on sustainable economic development and job creation through strategic capital allocation.
Investissement Quebec
A government-backed financial institution dedicated to fostering economic growth and industrial innovation within the Quebec region.
Desjardins Capital
An investment entity specializing in providing growth capital to small and medium-sized enterprises to drive long-term economic stability.
What's next for MY01?
With the recent capital deployment, MY01 is expected to scale its manufacturing and distribution capabilities to meet the growing demand for its perfusion sensing technology. The strategic focus will likely shift toward expanding its presence in major trauma centers and deepening its integration with hospital information systems to streamline data-driven decision-making. Furthermore, the company is poised to leverage its favorable reimbursement status to drive wider adoption across the healthcare continuum, solidifying its role as a standard-of-care provider in the management of compartment syndrome. Future growth will be anchored by continued clinical research and the potential expansion of its diagnostic portfolio to address related perfusion-based pathologies.
See full MY01 company page
